Study 2 of 3 for search of: extreme lateral disc
Previous Study Return to Search Results Next Study

Full Text View
Tabular View
No Study Results Posted
Related Studies
XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)
This study is currently recruiting participants.
Verified by NuVasive, July 2010
First Received: June 22, 2009   Last Updated: July 29, 2010   History of Changes
Sponsor: NuVasive
Information provided by: NuVasive
ClinicalTrials.gov Identifier: NCT00927238
  Purpose

The purpose of this study is to evaluate the safety and effectiveness of XL TDR in patients with single-level degenerative disc disease compared to other devices approved by the FDA for the same or similar indications.


Condition Intervention Phase
Degenerative Disc Disease
Device: XL TDR
Other: Lumbar fusion surgery
Phase III

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pivotal, Multi-Center, Clinical Trial Evaluating The Safety And Effectiveness of The Lumbar TDR Device In Patients With Single-Level Lumbar Degenerative Disc Disease

Further study details as provided by NuVasive:

Primary Outcome Measures:
  • Improvement in ODI [ Time Frame: December 2012 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Disc Height [ Time Frame: December 2012 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 300
Study Start Date: July 2009
Estimated Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
XL TDR: Experimental
The XL TDR is indicated for reconstruction of the disc following discectomy in skeletally mature subjects with symptomatic degenerative disc disease (DDD) of the lumbar spine at one level from L1-L5. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history radiographic studies.
Device: XL TDR
This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
Other: Lumbar fusion surgery
Lumbar fusion surgery
Outcomes from lumbar fusion study Other: Lumbar fusion surgery
Lumbar fusion surgery

Detailed Description:

The XL TDR® eXtreme Lateral Total Disc Replacement consists of two endplates that are provided in a number of sizes to accommodate a variety of patient anatomies and pathologies. The XL TDR device is made up of a ball and socket articulation and the joint is made of CoCrMo alloy.

The XL TDR is intended to be used to reconstruct the spine following the removal of part or all of the intervertebral disc on one level of the lumbar spine.

The XL TDR is indicated for reconstruction of the disc following discectomy in skeletally mature subjects with symptomatic degenerative disc disease (DDD) of the lumbar spine at one level from L1-L5. DDD is defined as discogenic back pain with degeneration of the disc confirmed by patient history radiographic studies.

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18-70 years of age (inclusive and skeletally mature) at the time of surgery
  • Diagnosis of image-confirmed symptomatic DDD at one of the following levels: L1/L2, L2/L3, L3/L4, or L4/L5
  • DDD diagnosed using patient history and image-confirmation such as (but not limited to), MRI, CT, or CT Myelogram with one or more of the following factors: contained herniated nucleus pulposus, facet joint degeneration/changes, decreased disc height >2mm, and/or scarring/thickening of ligamentum flavum, annulus fibrosis, or facet joint capsule
  • Preoperative ODI ≥ 30 points
  • Unresponsive to conservative treatment for ≥ 6 months

Exclusion Criteria:

  • Symptomatic multilevel lumbar degeneration
  • Chronic back or leg pain of unknown etiology
  • Non-contained or extruded herniated nucleus pulpous
  • Previous or other lumbar surgery at any level except prior discectomy, laminotomy, or nucleolysis at the same level
  • Involved vertebral endplates dimensionally smaller than 45mm in the medial-lateral and/or 20mm in the anterior/posterior directions
  • Idiopathic scoliosis
  • Defect in the pars interarticularis
  • Radiographic signs of significant instability at operative level
  • Lytic spondylolisthesis or degenerative spondylolisthesis > than grade 1
  • Bony lumbar spinal stenosis
  • Radiographic confirmation of significant facet joint disease or degeneration
  • Another lumbar device implanted
  • Clinically compromised vertebral bodies at the affected level due to trauma
  • Presence of metastases or active spinal tumor malignancy
  • Osteopenia, osteoporosis, or metabolic bone disease
  • Active local or systemic infection, including AIDS and hepatitis
  • Rheumatoid arthritis or other autoimmune disease
  • Taking any medications or supplements which potentially interfere with bone/soft tissue healing
  • Progressive neuromuscular disease
  • Allergy to device materials, specifically: cobalt-chromium-molybdenum alloy, titanium, and hydroxyapatite
  • BMI >40
  • Pregnant, or may become pregnant within follow-up period of study
  • Enrolled in another investigational study within the last 90 days
  • Waddell signs of inorganic behavior ≥3
  • History of substance abuse
  • Involved in active spinal litigation
  • Receiving workman's compensation for spinal condition
  • Mentally incompetent
  • Incarcerated
  • Unwilling or unable to comply with all protocol visits/assessments
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00927238

Locations
United States, California
Silicon Valley Spine Institute Recruiting
Campbell, California, United States, 95008
Contact: Amelia Panighetti     408-376-3311     amelia@svspine.com    
Principal Investigator: Jeffrey D Coe, MD            
UCSD Medical Center Withdrawn
San Diego, California, United States, 92103
Conejo Spine Recruiting
Thousand Oaks, California, United States, 91360
Contact: Erik Spayde, MD     805-379-2322        
Principal Investigator: Erik Spayde, MD            
United States, Colorado
Spine Colorado / Durango Orthopedic Associates Recruiting
Durango, Colorado, United States, 81301
Contact: Katie Patty     970-375-3696     kpatty@spinecolorado.com    
Principal Investigator: Jim Youssef, MD            
United States, Delaware
Christiana Spine Center Recruiting
Newark, Delaware, United States, 19713
Contact: Natalie Knitowski     302-623-4161     nuvasivestudy@christianaspinecenter.com    
Principal Investigator: Rush Fisher, MD            
United States, District of Columbia
Georgetown University Medical Center Recruiting
Washington, District of Columbia, United States, 20007
Contact: Lucy Kim, CCRP     202-444-1183     ilk3@georgetown.edu    
Principal Investigator: Faheem Sandhu, MD            
United States, Florida
South Florida Spine Institute Recruiting
Miami Beach, Florida, United States, 33140
Contact: Melissa Seits, PA-C     305-532-2411     mseits@southfloridaspine.com    
Principal Investigator: Jonathan Hyde, MD            
Southeastern Spine Center & Research Institute Recruiting
Sarasota, Florida, United States, 34342
Contact: Debbie Sobering     941-371-9773 ext 106        
Principal Investigator: Thomas M Sweeney, MD            
University of South Florida Recruiting
Tampa, Florida, United States, 33606
Contact: Debbie Scott, BA, CCRC     888-674-2326     xlmotion@nuvasive.com    
Principal Investigator: Juan Uribe, MD            
United States, Georgia
West Augusta Spine Specialists Recruiting
Augusta, Georgia, United States, 30909
Contact: Carolina Poteet     706-922-4450     bcp@knology.net    
Contact: James Polhill     706-724-9607        
Principal Investigator: IIdemaro Volcan, MD            
Sub-Investigator: Alan Goodrich, MD            
Sub-Investigator: Gregory Oetting, MD            
United States, Louisiana
Spine Institute of Louisiana Recruiting
Shreveport, Louisiana, United States, 71101
Contact: Ajay Jawahar, MD     318-629-5555     ajawahar@louisianaspine.org    
Principal Investigator: Pierce Nunley, MD            
United States, Missouri
Spine Midwest Recruiting
Jefferson City, Missouri, United States, 65101
Contact: Jamie Patterson     573-636-9000     jamie@spinemidwest.com    
Principal Investigator: Blake Rodgers, MD            
United States, Nevada
Western Regional Spine Center for Brain and Spine Surgery Recruiting
Las Vegas, Nevada, United States, 89109
Contact: Kyle Malone     702-851-0877     Kmalone@NNRF.net    
Contact: Ginger Christian     702-851-0877     gchristian@brainandspineonline.com    
Principal Investigator: William Smith, MD            
United States, New York
Buffalo Spine Surgery Recruiting
Lockport, New York, United States, 14094
Contact: Sarah Martineck     716-438-2973     diskstudy1@aol.com    
Contact: Faizah Shah     716-438-2973     diskstudy1@aol.com    
Principal Investigator: Andy Cappuccino, MD            
United States, Oregon
Southern Oregon Orthopedics Recruiting
Medford, Oregon, United States, 97504
Contact: Moni Peterson     541-608-2574     monip@oregonortho.com    
Principal Investigator: Mark Peterson, MD            
United States, South Carolina
Southeastern Spine Institute Recruiting
Mt. Pleasant, South Carolina, United States, 29464
Contact: Al Matus     843-849-1551 ext 138     al.matus@southeasternspine.com    
Principal Investigator: Donald Johnson, MD            
Sub-Investigator: Steven Poletti, MD            
United States, Texas
Central Texas Spine Institute Recruiting
Austin, Texas, United States, 78731
Contact: Amy Sasser     512-374-0677     asasser@pqrinc.com    
Contact: Celeste Figg     512-795-2225     cfigg@pqrinc.com    
Principal Investigator: Randall Dryer, MD            
United States, Washington
Swedish Spine Institute Recruiting
Seattle, Washington, United States, 98122
Contact: Megan Alexander     206-320-4355     Megan.Alexander@swedish.org    
Principal Investigator: Paul Schwaegler, MD            
Northwest Orthopaedic Specialists Recruiting
Spokane, Washington, United States, 99208
Contact: Mirna Tohmeh     509-465-1300     Tohmeh@comcast.net    
Principal Investigator: Antoine Tohmeh, MD            
Sub-Investigator: Melvin Wahl, MD            
Sub-Investigator: Matthew Fewel, MD            
Sponsors and Collaborators
NuVasive
Investigators
Principal Investigator: William D Smith, MD Western Regional Center for Brain and Spine Surgery
  More Information

Additional Information:
No publications provided

Responsible Party: Clinical Affairs Manager ( Julie Pairamore )
ClinicalTrials.gov Identifier: NCT00927238     History of Changes
Other Study ID Numbers: NUVA-LTDR-0701
Study First Received: June 22, 2009
Last Updated: July 29, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by NuVasive:
Single Level
Lumbar Disc Disease
DDD

Additional relevant MeSH terms:
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on September 01, 2010